

Gabriella d'Ettorre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4105752/publications.pdf>

Version: 2024-02-01

211
papers

4,460
citations

136740

32
h-index

174990

52
g-index

213
all docs

213
docs citations

213
times ranked

6818
citing authors

#	ARTICLE	IF	CITATIONS
1	Preventing influenza and influenza like illness during Covid-19 pandemic: A call for action. <i>Early Human Development</i> , 2022, 169, 105156.	0.8	4
2	Covid-19 sequelae in working age patients: A systematic review. <i>Journal of Medical Virology</i> , 2022, 94, 858-868.	2.5	26
3	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 257-266.	1.8	18
4	The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 803.	1.8	8
5	Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. <i>Viruses</i> , 2022, 14, 163.	1.5	5
6	Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19. <i>Microorganisms</i> , 2022, 10, 363.	1.6	4
7	HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 239.	2.1	24
8	Analysis of serum microRNAs and rs2910164 GC single-nucleotide polymorphism of miRNA-146a in COVID-19 patients. <i>Journal of Immunoassay and Immunochemistry</i> , 2022, 43, 347-364.	0.5	7
9	Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. <i>Diagnostics</i> , 2022, 12, 76.	1.3	9
10	Anti-IFN- λ 1/2 neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. <i>European Journal of Immunology</i> , 2022, 52, 1120-1128.	1.6	29
11	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055289.	0.8	1
12	High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19. <i>Clinical Immunology</i> , 2022, 241, 109068.	1.4	5
13	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. <i>Biomedicines</i> , 2022, 10, 1548.	1.4	2
14	Post-Traumatic Stress Disorder Trajectories the Year after COVID-19 Hospitalization. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8452.	1.2	10
15	qSOFA as a new community-acquired pneumonia severity score in the emergency setting. <i>Emergency Medicine Journal</i> , 2021, 38, 906-912.	0.4	3
16	Targeting the NO-GMP-PDE5 pathway in COVID-19 infection. The DEDALO project. <i>Andrology</i> , 2021, 9, 33-38.	1.9	47
17	Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 4-10.	0.5	9
18	Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13418.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial. <i>Journal of Medical Virology</i> , 2021, 93, 2210-2220.	2.5	22
20	Surveillance of COVID-19 in migrant reception centres: a call for action. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	7
21	Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 24-32.	0.8	22
22	Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2021, , 17-32.	0.8	3
23	First report of spondylodiscitis caused by <i>Bacillus circulans</i> in an immunocompetent patient: Clinical case and review of the literature. <i>IDCases</i> , 2021, 23, e01058.	0.4	4
24	Malaria in an asylum seeker paediatric liver transplant recipient: diagnostic challenges for migrant population. <i>Journal of Infection in Developing Countries</i> , 2021, 15, 172-178.	0.5	2
25	Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 601.	1.2	187
26	SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients. <i>Microorganisms</i> , 2021, 9, 93.	1.6	4
27	Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic. <i>Internal and Emergency Medicine</i> , 2021, 16, 541-543.	1.0	7
28	The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review. <i>Current HIV Research</i> , 2021, 19, 106-120.	0.2	3
29	Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge. <i>Journal of General Internal Medicine</i> , 2021, 36, 1702-1707.	1.3	98
30	Alzheimer's Dementia in People Living With HIV. <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000001060.	0.8	15
31	The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). <i>Journal of Medical Virology</i> , 2021, 93, 4319-4325.	2.5	20
32	Viral community acquired pneumonia at the emergency department: Report from the pre COVID-19 age. <i>Journal of Medical Virology</i> , 2021, 93, 4399-4404.	2.5	7
33	Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). <i>Virus Research</i> , 2021, 295, 198283.	1.1	26
34	The importance of genomic analysis in cracking the coronavirus pandemic. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 547-562.	1.5	14
35	Dysbiosis in SARS-CoV-2-Infected Patients. <i>Gastroenterology</i> , 2021, 160, 2195.	0.6	8
36	Alteration of type I interferon response is associated with subclinical atherosclerosis in virologically suppressed HIV-1-infected male patients. <i>Journal of Medical Virology</i> , 2021, 93, 4930-4938.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 478-485.	0.5	5
38	KI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients. <i>Microorganisms</i> , 2021, 9, 1259.	1.6	3
39	Early antibiotic treatment in emergency department: the critical balance. <i>Internal and Emergency Medicine</i> , 2021, 16, 1743-1745.	1.0	0
40	Efficacy and durability of twoâ€‹i>vs</i>. threeâ€‹drug integrase inhibitorâ€‹based regimens in virologically suppressed HIVâ€‹infected patients: Data from realâ€‹life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.	1.0	18
41	Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19. <i>Frontiers in Immunology</i> , 2021, 12, 708149.	2.2	35
42	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. <i>Internal and Emergency Medicine</i> , 2021, 16, 1231-1237.	1.0	20
43	Antiretroviral Therapy Dampens Mucosal CD4+ T Lamina Propria Lymphocytes Immune Activation in Long-Term Treated People Living with HIV-1. <i>Microorganisms</i> , 2021, 9, 1624.	1.6	1
44	Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II). <i>Diagnostics</i> , 2021, 11, 1368.	1.3	3
45	Oxygen Sparing Effect of Bacteriotherapy in COVID-19. <i>Nutrients</i> , 2021, 13, 2898.	1.7	9
46	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3784.	1.0	12
47	Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 234-237.	0.9	18
48	Cardiac involvement in consecutive unselected hospitalized COVID-19 population: In-hospital evaluation and one-year follow-up. <i>International Journal of Cardiology</i> , 2021, 339, 235-242.	0.8	28
49	Depressive Symptoms among Individuals Hospitalized with COVID-19: Three-Month Follow-Up. <i>Brain Sciences</i> , 2021, 11, 1175.	1.1	9
50	CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia. <i>Infezioni in Medicina</i> , 2021, 29, 408-415.	0.7	4
51	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. <i>Thrombosis and Haemostasis</i> , 2021, 121, 102-105.	1.8	36
52	Human Immunodeficiency Virus Type 2: The Neglected Threat. <i>Pathogens</i> , 2021, 10, 1377.	1.2	11
53	SARS-CoV-2 Among Migrants Recently Arrived in Europe From Low- and Middle-Income Countries: Containment Strategies and Special Features of Management in Reception Centers. <i>Frontiers in Public Health</i> , 2021, 9, 735601.	1.3	2
54	Clinical Effects of Oral Bacteriotherapy on Anal HPV Infection and Related Dysplasia in HIV-Positive MSM: Results from the â€‹HPV in HIVâ€‹Trial. <i>Biomedicines</i> , 2021, 9, 1738.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients. <i>Frontiers in Nutrition</i> , 2021, 8, 756177.	1.6	6
56	Lesson learned from the 2017 measles outbreak in Italy: report from an emergency department. <i>Infezioni in Medicina</i> , 2021, 29, 252-258.	0.7	1
57	590â€™ACE-I and ARBS do not influence the chest CT presentation and 1-year survival of COVID-19 patients: Italian multicentre registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
58	Physical Activity and HIV: Effects on Fitness Status, Metabolism, Inflammation and Immune-Activation. <i>AIDS and Behavior</i> , 2020, 24, 1042-1050.	1.4	9
59	Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 298-303.	0.9	13
60	Carotid Artery Aneurysm in HIV: A Review of Case Reports in Literature. <i>Annals of Vascular Surgery</i> , 2020, 63, 409-426.	0.4	5
61	Cognitive impairment and CSF proteome modification after oral bacteriotherapy in HIV patients. <i>Journal of NeuroVirology</i> , 2020, 26, 95-106.	1.0	9
62	Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help?. <i>Antibiotics</i> , 2020, 9, 644.	1.5	2
63	Retinal involvement and ocular findings in COVID-19 pneumonia patients. <i>Scientific Reports</i> , 2020, 10, 17419.	1.6	65
64	High abundance of genus <i>Prevotella</i> is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients. <i>Aids</i> , 2020, 34, 1467-1473.	1.0	14
65	Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial. <i>Metabolites</i> , 2020, 10, 274.	1.3	7
66	Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 389.	1.2	152
67	Comparison Between Hospitalized Patients Affected or Not Affected by Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 72, e1158-e1159.	2.9	7
68	Probiotics and COVID-19. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 721-722.	3.7	32
69	Nox2 activation in Covid-19. <i>Redox Biology</i> , 2020, 36, 101655.	3.9	114
70	Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1323, 103-114.	0.8	14
71	Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection. <i>Medicine (United States)</i> , 2020, 99, e21803.	0.4	18
72	Is previous influenza-like illness a potential Trojan horse for COVID-19?. <i>Critical Care</i> , 2020, 24, 503.	2.5	10

#	ARTICLE	IF	CITATIONS
73	Efficacy of Daptomycin-Containing Regimen for Treatment of Staphylococcal or Enterococcal Vertebral Osteomyelitis: A Prospective Clinical Experience. <i>Antibiotics</i> , 2020, 9, 889.	1.5	3
74	Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients. <i>Biology of Sex Differences</i> , 2020, 11, 23.	1.8	11
75	Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients. <i>Journal of Clinical Virology</i> , 2020, 128, 104450.	1.6	10
76	Is teicoplanin a complementary treatment option for COVID-19? The question remains. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106029.	1.1	41
77	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , 2020, 127, 400-401.	2.0	60
78	Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. <i>Nutrients</i> , 2020, 12, 1718.	1.7	155
79	Antibacterial Effectiveness of Fecal Water and In Vitro Activity of a Multi-Strain Probiotic Formulation against Multi-Drug Resistant Microorganisms. <i>Microorganisms</i> , 2020, 8, 332.	1.6	2
80	Real world outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 485-492.	2.0	4
81	High HIV-1 diversity in immigrants resident in Italy (2008â€“2017). <i>Scientific Reports</i> , 2020, 10, 3226.	1.6	8
82	JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis. <i>Virology Journal</i> , 2020, 17, 23.	1.4	20
83	Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. <i>Frontiers in Nutrition</i> , 2020, 7, 613928.	1.6	55
84	Monocyte absolute count as a preliminary tool to distinguish between SARS-CoV-2 and influenza A/B infections in patients requiring hospitalization. <i>Infezioni in Medicina</i> , 2020, 28, 534-538.	0.7	2
85	A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected Patients. <i>Antiviral Therapy</i> , 2019, 24, 63-67.	0.6	33
86	Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naÃ“ve patients: results from a multicenter cohort study. <i>Antiviral Research</i> , 2019, 169, 104552.	1.9	23
87	Diagnostic Issues of Asymptomatic Neurosyphilis in HIV-Positive Patients: A Retrospective Study. <i>Brain Sciences</i> , 2019, 9, 278.	1.1	13
88	Infected chronic ischemic wound topically treated with a multi-strain probiotic formulation: a novel tailored treatment strategy. <i>Journal of Translational Medicine</i> , 2019, 17, 364.	1.8	20
89	Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virus. <i>Critical Care</i> , 2019, 23, 330.	2.5	30
90	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 728-734.	1.1	40

#	ARTICLE	IF	CITATIONS
91	Short-Term Probiotic Administration Increases Fecal-Anti Candida Activity in Healthy Subjects. <i>Microorganisms</i> , 2019, 7, 162.	1.6	6
92	Many Different Patterns under a Common Flag: Aortic Pathology in HIV – A Review of Case Reports in Literature. <i>Annals of Vascular Surgery</i> , 2019, 59, 268-284.	0.4	19
93	Impact of the 2017 measles outbreak on the emergency care system of a large tertiary-care teaching hospital in Italy: a retrospective analysis. <i>European Journal of Public Health</i> , 2019, 29, 966-971.	0.1	8
94	Increased expression of IL-32 correlates with IFN- γ , Th1 and Tc1 in virologically suppressed HIV-1-infected patients. <i>Cytokine</i> , 2019, 120, 273-281.	1.4	12
95	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. <i>Aids</i> , 2019, 33, 759-762.	1.0	19
96	Increased IL-17 and/or IFN- γ producing T-cell subsets in gut mucosa of long-term-treated HIV-1-infected women. <i>Aids</i> , 2019, 33, 627-636.	1.0	7
97	Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 679-691.	2.6	7
98	Myeloid and lymphoid activation markers in AIDS and non-AIDS presenters. <i>Immunobiology</i> , 2019, 224, 231-241.	0.8	8
99	Antiviral Activity of Fecal Water Samples from HIV-1 Infected Subjects Treated with a Specific Probiotic Formulation. <i>Current HIV Research</i> , 2019, 17, 183-189.	0.2	1
100	Fecal Microbial Transplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent <i>Clostridium difficile</i> infection patients. <i>New Microbiologica</i> , 2019, 42, 221-224.	0.1	7
101	Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 319-329.	0.7	33
102	Interferon lambda4 polymorphism is not associated with human papillomavirus infection outcome. <i>Virus Genes</i> , 2018, 54, 319-322.	0.7	2
103	Clearance of human papillomavirus related anal condylomas after oral and endorectal multistrain probiotic supplementation in an HIV positive male. <i>Medicine (United States)</i> , 2018, 97, e0329.	0.4	7
104	Single-Strain Versus Multistrain Probiotic Supplementation Treatment Strategy for Rheumatoid Arthritis: Comment on the Article by Marietta et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 320-321.	2.9	2
105	Type I/II Interferon in HIV-1-Infected Patients: Expression in Gut Mucosa and in Peripheral Blood Mononuclear Cells and Its Modification upon Probiotic Supplementation. <i>Journal of Immunology Research</i> , 2018, 2018, 1-7.	0.9	14
106	HIV-2 Infection in a Migrant from Gambia: The History of the Disease Combined with Phylogenetic Analysis Revealed the Real Source of Infection. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 1090-1094.	0.5	3
107	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	1.3	29
108	Systemic adipokines, hepatokines and interleukin-6 in HCV-monoinfected and HCV/HIV coinfecting patients treated with direct antiviral agents (DAAs). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, e45-e48.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2055-2059.	1.3	28
110	Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir. <i>Archives of Virology</i> , 2017, 162, 2565-2577.	0.9	11
111	Probiotic supplementation promotes a reduction in T cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1 positive patients. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 244-260.	1.3	84
112	A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA levels in antiretroviral-treated HIV-1 infected patients. <i>Brain and Behavior</i> , 2017, 7, e00756.	1.0	45
113	Modulation of Tryptophan/Serotonin Pathway by Probiotic Supplementation in Human Immunodeficiency Virus-Positive Patients: Preliminary Results of a New Study Approach. <i>International Journal of Tryptophan Research</i> , 2017, 10, 117864691771066.	1.0	22
114	Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study. <i>Current HIV Research</i> , 2017, 15, 355-360.	0.2	6
115	Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals. <i>Nutrients</i> , 2017, 9, 1269.	1.7	38
116	Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. <i>BMC Infectious Diseases</i> , 2017, 17, 581.	1.3	34
117	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2017, 17, .	0.5	0
118	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	1.3	62
119	Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1639.	1.8	18
120	Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients. <i>PLoS ONE</i> , 2016, 11, e0149601.	1.1	14
121	Dominant enrichment of phenotypically activated CD38 ⁺ HLA-DR ⁺ CD8 ⁺ T cells, rather than CD38 ⁺ HLA-DR ⁺ CD4 ⁺ T cells, in HIV/HCV coinfecting patients on antiretroviral therapy. <i>Journal of Medical Virology</i> , 2016, 88, 1347-1356.	2.5	5
122	Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis. <i>HIV Clinical Trials</i> , 2016, 17, 49-54.	2.0	10
123	Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1257-1262.	0.6	14
124	What happens to cardiovascular system behind the undetectable level of HIV viremia?. <i>AIDS Research and Therapy</i> , 2016, 13, 21.	0.7	29
125	IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. <i>Archives of Virology</i> , 2016, 161, 3263-3268.	0.9	3
126	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. <i>BMC Infectious Diseases</i> , 2016, 16, 401.	1.3	6

#	ARTICLE	IF	CITATIONS
127	Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAZANAVIR & GLUCOSE metabolism (ATAGLU) study. <i>International Journal of STD and AIDS</i> , 2016, 27, 638-643.	0.5	5
128	IFN- γ promotes rapid human Treg contraction and late Th1-like Treg decrease. <i>Journal of Leukocyte Biology</i> , 2016, 100, 613-623.	1.5	9
129	Apoptotic Epitope-Specific CD8 ⁺ T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 674-683.	1.9	8
130	ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response. <i>Immunobiology</i> , 2016, 221, 282-290.	0.8	32
131	The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant <i>Acinetobacter baumannii</i> causing severe infections in a Paediatric Intensive Care Unit. <i>BMC Infectious Diseases</i> , 2015, 15, 393.	1.3	20
132	An epidemiological investigation to reconstruct a probable human immunodeficiency virus -1 transmission network: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 253.	0.4	0
133	Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV" Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0137200.	1.1	120
134	Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	15
135	HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. <i>Current HIV Research</i> , 2015, 13, 250-257.	0.2	37
136	Trends in drug resistance-associated mutations in a real-life cohort of Italian patients infected with HIV-1. <i>Journal of Global Antimicrobial Resistance</i> , 2015, 3, 267-272.	0.9	7
137	MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients. <i>BMC Infectious Diseases</i> , 2015, 15, 51.	1.3	26
138	Thymosin α 1 potentiates the release by CD8 ⁺ cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 83-100.	1.4	12
139	Dynamics of HIV DNA and Residual Viremia in Patients Treated With a Raltegravir-Containing Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, e18-e20.	0.9	4
140	Mobile Phone Microbial Contamination Among Neonatal Unit Healthcare Workers. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 487-489.	1.0	8
141	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 71-77.	0.5	9
142	Normocaloric Low Cholesterol Diet Modulates Th17/Treg Balance in Patients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2014, 9, e112346.	1.1	29
143	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 34-45.	1.5	23
144	Taming HIV-Related Inflammation with Physical Activity: A Matter of Timing. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 936-944.	0.5	45

#	ARTICLE	IF	CITATIONS
145	Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 53, 567-73.	1.4	23
146	Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. <i>Medical Microbiology and Immunology</i> , 2014, 203, 207-16.	2.6	20
147	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 35-40.	0.5	4
148	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e109791.	1.1	26
149	Urinary Schistosomiasis in Asylum Seekers in Italy: An Emergency Currently Undervalued. <i>Journal of Immigrant and Minority Health</i> , 2013, 15, 846-850.	0.8	14
150	HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity. <i>Journal of NeuroVirology</i> , 2013, 19, 274-279.	1.0	19
151	Buschke-Lowenstein tumor with squamous cell carcinoma treated with chemo-radiation therapy and local surgical excision: report of three cases. <i>World Journal of Surgical Oncology</i> , 2013, 11, 231.	0.8	21
152	Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 732-739.	0.8	65
153	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 193-199.	1.3	10
154	An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1254-1259.	0.5	6
155	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1365-1369.	0.5	2
156	Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. <i>FASEB Journal</i> , 2013, 27, 2440-2450.	0.2	75
157	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e80157.	1.1	35
158	Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. <i>Isrn Aids</i> , 2013, 2013, 1-6.	2.5	6
159	Gut Microbial Translocation in Critically Ill Children and Effects of Supplementation with Pre- and Pro Biotics. <i>International Journal of Microbiology</i> , 2012, 2012, 1-8.	0.9	31
160	Microbial Translocation and Infectious Diseases: What Is the Link?. <i>International Journal of Microbiology</i> , 2012, 2012, 1-2.	0.9	8
161	Prevalence of Prolonged Amenorrhea in HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, e19-e21.	0.9	6
162	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. <i>Cytokine</i> , 2012, 57, 54-60.	1.4	6

#	ARTICLE	IF	CITATIONS
163	Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects. <i>Journal of Infection</i> , 2012, 64, 82-88.	1.7	24
164	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. <i>Pharmacological Research</i> , 2011, 63, 249-253.	3.1	23
165	HIV-Associated Immune Activation: From Bench to Bedside. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 355-364.	0.5	105
166	Diagnosis of anal human papillomavirus infection: polymerase chain reaction or cytology?. <i>International Journal of Infectious Diseases</i> , 2011, 15, e232-e235.	1.5	3
167	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. <i>Current HIV Research</i> , 2011, 9, 148-153.	0.2	68
168	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. <i>BMC Infectious Diseases</i> , 2011, 11, 341.	1.3	7
169	Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 70.	0.4	9
170	Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: case report and review of the literature. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 262-265.	0.3	5
171	Expression of the mRNA Levels for MDR1, MRP1, MRP4, and MRP5 IN HIV Antiretroviral Naive Patients: Follow-up at 48 Weeks After the Beginning of Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e54-e56.	0.9	3
172	Timed Short Messaging Service Improves Adherence and Virological Outcomes in HIV-1-Infected Patients With Suboptimal Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e113-e115.	0.9	24
173	Severe and Persistent Depletion of Circulating Plasmacytoid Dendritic Cells in Patients with 2009 Pandemic H1N1 Infection. <i>PLoS ONE</i> , 2011, 6, e19872.	1.1	31
174	Mutational Resistance Pattern of HIV Type 1 in CD14 ⁺ Monocytes, CD4 ⁺ T Cells, and Plasma from Treated Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 625-634.	0.5	6
175	Expression Levels of TLRs Involved in Viral Recognition in PBMCs from HIV-1-Infected Patients Failing Antiretroviral Therapy. <i>Intervirolgy</i> , 2009, 52, 107-114.	1.2	22
176	DC contact with HIV-1-infected cells leads to high levels of Env-mediated virion endocytosis coupled with enhanced HIV-1 Ag presentation. <i>European Journal of Immunology</i> , 2009, 39, 404-416.	1.6	7
177	Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation. <i>Journal of Medical Virology</i> , 2009, 81, 400-405.	2.5	49
178	Hospital-acquired infection surveillance in a neonatal intensive care unit. <i>American Journal of Infection Control</i> , 2009, 37, 201-203.	1.1	52
179	HIV-1 Residual Viremia and Proviral DNA in Patients with Suppressed Plasma Viral Load (<math><lt; 400\text{ Tj ETQq1 1 0.784314 rgBT /Overloc}</math>)	0.2	31
180	Type-specific human papillomavirus-DNA load in anal infection in HIV-positive men. <i>Aids</i> , 2008, 22, 1929-1935.	1.0	30

#	ARTICLE	IF	CITATIONS
181	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. <i>HIV Clinical Trials</i> , 2007, 8, 182-188.	2.0	6
182	Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 518-524.	0.9	35
183	Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007, 79, 111-117.	2.5	15
184	Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. <i>Journal of Medical Virology</i> , 2007, 79, 880-886.	2.5	22
185	Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. <i>Nature Medicine</i> , 2007, 13, 1431-1439.	15.2	74
186	Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. <i>Acta Tropica</i> , 2006, 99, 83-87.	0.9	16
187	Interleukin-15 enhances the secretion of IFN- $\hat{1}^3$ and CC chemokines by natural killer cells from HIV viremic and aviremic patients. <i>Immunology Letters</i> , 2006, 103, 192-195.	1.1	19
188	Apoptotic Cell Signaling in Lymphocytes from HIV+ Patients during Successful Therapy. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 130-137.	1.8	4
189	Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2233-2241.	0.9	2
190	Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. <i>Aids</i> , 2005, 19, 841-842.	1.0	6
191	Abdominal aortic mycotic aneurysm, psoas abscess, and aorto-bisiliac graft infection due to <i>Salmonella typhimurium</i> . <i>Journal of Infection and Chemotherapy</i> , 2005, 11, 297-299.	0.8	5
192	Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2005, 43, 6183-6185.	1.8	21
193	Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 816-818.	0.5	13
194	Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 494-500.	1.3	9
195	Viral growth assay to evaluate the replicative capacity of HIV-1 isolates. <i>Journal of Virological Methods</i> , 2004, 115, 199-205.	1.0	2
196	Interleukin-15 modulates interferon- $\hat{1}^3$ and $\hat{1}^2$ -chemokine production in patients with HIV infection: implications for immune-based therapy. <i>Cytokine</i> , 2004, 25, 283-290.	1.4	18
197	Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy?. <i>Trends in Immunology</i> , 2004, 25, 121-125.	2.9	39
198	Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2003, 69, 1-6.	2.5	59

#	ARTICLE	IF	CITATIONS
199	Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1760-1762.	1.8	28
200	High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3007-3012.	1.8	14
201	Discordance between Genotypic and Phenotypic Drug Resistance Profiles in Human Immunodeficiency Virus Type 1 Strains Isolated from Peripheral Blood Mononuclear Cells. <i>Journal of Clinical Microbiology</i> , 2002, 40, 335-340.	1.8	14
202	Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. <i>Aids</i> , 2002, 16, 181-188.	1.0	56
203	Discordant response to antiretroviral therapy. <i>Aids</i> , 2002, 16, 1877-1885.	1.0	18
204	Human immunodeficiency virus-1 specific and natural cellular immunity in HIV seronegative subjects with multiple sexual exposures to virus. <i>Journal of Medical Virology</i> , 2001, 64, 232-237.	2.5	11
205	Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-Like HIV-1 resistance mutations. <i>Journal of Medical Virology</i> , 2001, 65, 631-636.	2.5	12
206	Neutralizing Antibodies against Autologous Human Immunodeficiency Virus Type 1 Isolates in Patients with Increasing CD4 Cell Counts despite Incomplete Virus Suppression during Antiretroviral Treatment. <i>Vaccine Journal</i> , 2001, 8, 822-824.	2.6	6
207	Rhabdomyolysis after cerivastatin/gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. <i>Aids</i> , 2001, 15, 820-821.	1.0	35
208	Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 1979-1984.	0.6	42
209	Ex Vivo and In Vitro Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Apoptosis. <i>Journal of Infectious Diseases</i> , 2000, 182, 1536-1539.	1.9	34
210	Overexpression of Lymphocytic GD3 Ganglioside and Presence of Anti-GD3 Antibodies in Patients with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1539-1549.	0.5	9
211	Changes in Circulating Levels of Soluble Cell Adhesion Molecules Following Highly Active Antiretroviral Treatment of HIV-1-Infected Patients. <i>Clinical Immunology</i> , 2000, 95, 212-217.	1.4	17